Effect of community treatment initiative on antiretroviral therapy uptake among linkage-resistant people living with HIV in Northern Nigeria.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 20 02 2019
revised: 28 07 2019
accepted: 15 08 2019
pubmed: 26 8 2019
medline: 18 12 2019
entrez: 26 8 2019
Statut: ppublish

Résumé

Community Treatment Initiative (CTI) was developed in northern Nigeria as an intervention to link a cohort of people living with HIV (PLHIV) who refused antiretroviral treatment through a conventional linkage method to care and treatment. The CTI attempted to take treatment to PLHIV in the community. This was a non-control interventional study that evaluated the proportion of linkage-resistant PLHIV linked to treatment through the CTI in nine geographical areas. Data were collected between October and December 2015. Linkage-resistant PLHIV were identified and linked to treatment using the CTI. Data were analyzed using Excel and IBM SPSS version 20.0. The simple proportion was used to estimate the linkage-resistant PLHIV who were eventually linked and retained in care and who ultimately achieved virological suppression (viral load <1000 copies/ml). The Chi-square test was used and the level of significance set at a p-value of <0.05. An estimated 541 (20%) PLHIV (239 (44.2%) male, 302 (55.8%) female) seen from October to December 2015 refused linkage to treatment. This was statistically significant at a p-value of <0.0001. Three hundred and seventy-seven (69.7%) of the PLHIV who refused linkage to treatment eventually accepted treatment using an alternative community treatment method; this was significant (p<0.0001). The 6-month retention rate for PLHIV who accepted the alternative treatment method was 88.1% (n=332); this was significant (p<0.0001). Seventy-eight percent of those retained in care attained virological suppression. The CTI improved linkage to care and treatment for a cohort of linkage-resistant PLHIV. Focus on this cohort of linkage-resistant positive clients is required to achieve HIV epidemic control.

Sections du résumé

BACKGROUND BACKGROUND
Community Treatment Initiative (CTI) was developed in northern Nigeria as an intervention to link a cohort of people living with HIV (PLHIV) who refused antiretroviral treatment through a conventional linkage method to care and treatment. The CTI attempted to take treatment to PLHIV in the community.
METHODS METHODS
This was a non-control interventional study that evaluated the proportion of linkage-resistant PLHIV linked to treatment through the CTI in nine geographical areas. Data were collected between October and December 2015. Linkage-resistant PLHIV were identified and linked to treatment using the CTI. Data were analyzed using Excel and IBM SPSS version 20.0. The simple proportion was used to estimate the linkage-resistant PLHIV who were eventually linked and retained in care and who ultimately achieved virological suppression (viral load <1000 copies/ml). The Chi-square test was used and the level of significance set at a p-value of <0.05.
RESULTS RESULTS
An estimated 541 (20%) PLHIV (239 (44.2%) male, 302 (55.8%) female) seen from October to December 2015 refused linkage to treatment. This was statistically significant at a p-value of <0.0001. Three hundred and seventy-seven (69.7%) of the PLHIV who refused linkage to treatment eventually accepted treatment using an alternative community treatment method; this was significant (p<0.0001). The 6-month retention rate for PLHIV who accepted the alternative treatment method was 88.1% (n=332); this was significant (p<0.0001). Seventy-eight percent of those retained in care attained virological suppression.
CONCLUSIONS CONCLUSIONS
The CTI improved linkage to care and treatment for a cohort of linkage-resistant PLHIV. Focus on this cohort of linkage-resistant positive clients is required to achieve HIV epidemic control.

Identifiants

pubmed: 31446175
pii: S1201-9712(19)30340-6
doi: 10.1016/j.ijid.2019.08.014
pii:
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

185-192

Informations de copyright

Published by Elsevier Ltd.

Auteurs

Moses Katbi (M)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: mkatbi@usaid.gov.

Adeoye Ayodeji Adegboye (AA)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: aadegboye@ihvnigeria.org.

Maryam Bello (M)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: mbello@ihvnigeria.org.

Aliyu Gambo Gumel (AG)

Institute of Human Virology, University of Maryland School of Medicine, 655 W. Baltimore Street, Baltimore, MD 21201, USA. Electronic address: galiyu@som.umaryland.edu.

Adefisayo Adedoyin (A)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: aadedoyin@ihvnigeria.org.

Fadimatu Yunusa (F)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: fyunusa@ihvnigeria.org.

Gbenga Kayode (G)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: gkayode@ihvnigeria.org.

Oche Baba Yusuf (OB)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: oyusuf@ihvnigeria.org.

Atinuke Anjorin (A)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: aomanayi@ihvnigeria.org.

Chizoba Geraldine Abone (CG)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: gabone@ihvnigeria.org.

Amalachukwu Ukaere (A)

DevTech Systems, Abuja, Nigeria. Electronic address: amala.solina@gmail.com.

Ernest Ekong (E)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: eekong@ihvnigeria.org.

Charles Mensah (C)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: cmensah@ihvnigeria.org.

Patrick Dakum (P)

Institute of Human Virology Nigeria, Pent House, Maina Court, Plot 252, Herbert Macaulay Way, Central Business District, P.O. Box 9396, Garki, Abuja, Nigeria. Electronic address: pdakum@ihvnigeria.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH